A retrospective study of 62 patients with primary
hepatocellular carcinoma in our hospital from January 2017 to December 2018 [60 males, 2 females, age (52.76 ± 10.82) years old], All patients were implanted with
Iodine-125 radioactive seeds under CT guidance, followed up regularly after operation to observe the clinical efficacy, including comparison of changes in
cancer size before and
after treatment,
tumor marker AFP, and improvement in complications such as
abdominal pain and
ascites. Follow-up 3-36 months to assess patient survival.
RESULTS: Among the 62 patients, 3 months after
Iodine-125 radioactive seed implantation, 5 cases (8.1%) had complete remission of
cancer, 33 cases (53.2%) had partial remission, 12 cases (19.4%) had stable lesions, and 12 cases (19.4%) had
disease progression. The effective rate was 61.3%. The
tumor volume (31.44 ± 14.51cm3) was significantly smaller than before (50.96 ± 30.13cm3) (t = 5.303, p < 0.05). The
tumor marker AFP (69.28 ± 50.99) ug/L of 3 months after implantation was significantly lower than that before treatment (90.63 ± 68.58) ug/L (t = 3.702, P < 0.05). The average survival time of
Iodine-125 seed implantation for stageⅣhepatocellular
carcinoma is 11.47 ± 0.85 months, and the median survival time is 9 months. The survival time of the group with better pathological differentiation (gradeⅠ+Ⅱ) was significantly better than that of the group with poor differentiation (grade Ⅲ+Ⅳ) (x2 = 6.869 p < 0.05). Among the 38 patients with different degrees of
abdominal pain, 22 patients improved better than before; 15 of 28 patients with different degrees of
ascites were better than before. All patients had no serious complications related to treatment.
CONCLUSIONS: